| Product name | Digoxin Monoclonal Antibody |
| Immunogen | Digoxin |
| Host | Mouse |
| Applications | ELISA |
| Applications notes | Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: ELISA 1:10000 |
| Clonality | Monoclonal |
| Preparation method | The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. |
| Alternative | Digoxin |
| Formulation | Liquid solution |
| Concentration | 1 mg/ml |
| Storage instructions | Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing. |
| Shipping | Gel pack with blue ice. |
| Precautions | The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product. |
| Background | The most common indications for digoxin are atrial fibrillation and atrial flutter with rapid ventricular response, though beta blockers and/or calcium channel blockers are a better first choice. There is tentative evidence that digoxin may increase the risk of death, though another meta-analysis reports no change in mortality. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves, owing to improved filling. |
| Alternative | Digoxin |
You must be logged in to post a review.
Reviews
There are no reviews yet.